Gabelli Makes Three Real Time Buys from the Tech Sector

Author's Avatar
Sep 19, 2013
Article's Main Image
Over the past week, Mario Gabelli has made several guru real time transactions. These transactions involve one new buy and an increase in two others. These real time picks represent purchases or sales of a stock in which a guru owns greater than a 5% stake. These real time picks help to keep you more closely informed.

Trans-Lux Corp. (TNLX)


On Sept. 13 Gabelli made his first buy into Trans-Lux. The guru bought a total of 10,087,100 shares of the company’s stock. He bought these shares at an average price of $0.125 per share. Since his buy the price has increased 60% to $0.20 per share.

Gabelli previously held on to Trans-Lux but closed out his position in 2011Q1. His updated position is the largest stake he’s ever taken with the company, with 38.92% of the company’s shares outstanding.

Gabelli’s historical holding history:

1379619559368.png

The company is a designer and manufacturer of digital signage display solutions. The essential elements of these systems are the real-time, programmable digital displays the company designs, manufactures, distributes and services.

Trans-Lux’s historical revenue and net income:

1379619831615.png

The analysis on the company reports that the company’s revenue has been in decline over the past five years, its operating margin is expanding and its price is sitting at a two-year low.

The company has recently announced several updates to its LED sector. You can read more about these updates here.

Trans-Lux has a market cap of $5.2 million. Its shares are currently trading at around $0.20 with a P/E ratio of 0.40, a P/S ratio of 0.30 and a P/B ratio of 6.70.

Gabelli is the only guru that maintains a position in Trans-Lux.

Bel Fuse (BELFA)

Over the past week Gabelli increased his position in Bel Fuse. On Sept. 16 Gabelli upped his stake 45.13% by adding 107,959 shares. He bought these shares at an average price of $17.55 per share, and today the price is trading slightly up at $17.61 per share.

As of his most recent buy, Gabelli holds on to 347,159 shares representing 3.04% of the company’s shares outstanding.

Gabelli’s holding history as of the second quarter:

1379620581549.png

The company designs, manufactures and markets magnetic, modules, and circuit protection devices and interconnect products. These products are designed to protect, regulate, connect, isolate or manage electronic circuits.

Bel Fuse’s historical revenue and net income:

1379620809385.png

The analysis on Bel Fuse reports:

· The dividend yield is close to a 1-year low.

· The price is nearing a 1-year high.

· The company holds enough cash to cover its debt.

· Its asset growth is faster than its revenue growth.

The Peter Lynch Chart suggests that the company is currently overvalued:

1379621089087.png

Bel Fuse has a market cap of $200.9 million. Its shares are currently trading at around $17.61 with a P/E ratio of 103.10, a P/S ratio of 0.70 and a P/B ratio of 0.90.

Gabelli, Chuck Royce and Jim Simons hold a stake in BELFA.

Rochester Medical (ROCM)

Gabelli has been consistently upping his stake in Rochester Medical throughout the month of September. The guru has made four different buys, adding a total of 432,006 shares to his stake. During the past month he’s bought these stocks in the price range of $19.87 to $19.91 per share. The price is trading slightly up at $19.22 per share.

As of his most recent buy happening on Sept. 18, Gabelli holds on to 942,516 shares of Rochester Medical, representing approximately 9.1% of the company’s shares outstanding.

Gabelli’s holding history as of the second quarter:

1379621616275.png

Rochester Medical develops, manufactures and markets, domestically and internationally, a broad line of innovative, technologically enhanced PVC-free and latex-free urinary continence and urine drainage care products for the home and acute care markets.

Rochester Medical’s historical revenue and net income:

1379621689147.png

The analysis on Rochester Medical reports that the company has no debt, its price is at a 5-year high and its P/S ratio is nearing a 3-year high.

The company released on Sept. 4, that it would be acquired by C.R. Bard for approximately $262 million.

The Peter Lynch Chart suggests that the company is currently overvalued:

1379621689147.png

Rochester Medical has a market cap of $246.2 million. Its shares are currently trading at around $19.92 with a P/E ratio of 57.20, a P/S ratio of 3.70 and a P/B ratio of 3.40. Rochester Medical had an annual average earnings growth of 1.8% over the past ten years.

Gabelli, Jim Simons and Robert Bruce all maintain a position in Rochester Medical.

You can check out Mario Gabelli’s real time picks here.

Try a free 7-day premium membership.